Friday, January 15, 2016

ESSA Pharma Closes $15M Funding

Houston-based prostate cancer treatment company ESSA Pharma says it has completed a previously announced, $15M private placement, which came from Clarus Lifesciences, along with Deerfield Management Company and other investors. The investment in publicly held ESSA Pharma was announced on January 6th. Scott Requadt of Clarus Ventuers has joined the company's board. ESSA Pharma--like many other biotech companies--is publicly held, but still supported by traditional venture investors.